AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

AbbVie (ABBV) announced a $195M investment in its North Chicago, Illinois manufacturing plant to expand domestic active ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...